Literature DB >> 925929

Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans.

L I Harrison, M Gibaldi.   

Abstract

A physiologically based pharmacokinetic model for digoxin disposition developed in the rat was modified to account for the interspecies differences in tissue-to-plasma digoxin concentration ratios and applied to the dog. The model provided a quantitative assessment of the time course of digoxin concentrations in dog plasma, various tissues, and urine. It also predicted the effect of renal failure on digoxin pharmacokinetics in the dog. An attempt to scale the dog model to humans by simply considering differences in organ volumes, organ flow rates, and digoxin clearances was partially successful. Good predictions of plasma digoxin concentration and urinary digoxin excretion after a single dose and of steady-state plasma, heart, and skeletal muscle digoxin concentrations were obtained. However, the model predicted considerably higher kidney digoxin concentrations than are actually found. Although the model adequately characterized the time course of digoxin concentrations in patients with moderate renal impairment, it provided a relatively poor fit to that observed in anuric patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 925929     DOI: 10.1002/jps.2600661206

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  25 in total

1.  A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog.

Authors:  K Dietzel; V Keuth; K S Estes; M E Brewster; R M Clemmons; R Vistelle; N S Bodor; H Derendorf
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 2.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Significance of binding to Na,K-ATPase in the tissue distribution of ouabain in guinea pigs.

Authors:  H Harashima; M Mamiya; M Yamazaki; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

4.  Kinetic modeling of ouabain tissue distribution based on slow and saturable binding to Na,K-ATPase.

Authors:  H Harashima; M Mamiya; M Yamazaki; Y Sawada; T Iga; M Hanano; Y Sugiyama
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

Review 5.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 6.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

Review 7.  Physiologically based pharmacokinetic models for anticancer drugs.

Authors:  H S Chen; J F Gross
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 8.  Pulmonary disease and drug kinetics.

Authors:  P du Souich; A J McLean; D Lalka; S Erill; M Gibaldi
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

9.  The pharmacokinetics of amygdalin.

Authors:  A G Rauws; M Olling; A Timmerman
Journal:  Arch Toxicol       Date:  1982-03       Impact factor: 5.153

10.  Theoretical consideration of drug distribution kinetics in a noneliminating organ: comparison between a "homogeneous (well-stirred)" model and "nonhomogeneous (tube)" model.

Authors:  T Terasaki; Y Sugiyama; T Iga; Y Sawada; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1985-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.